I am an Inventor, Organic Chemist and CEO at Kenneth Pharmaceuticals Inc. Our company emerges from (3) Graduate Education in the United State focusing on the Synthesis of Novel-disaccharide, Monosaccharides, and Tryptophan Analogs for Pharmaceutical Applications. These active Pharmaceutical Ingredients are precursors to New medicine and therapeutics. I have gained in-depth Scientific experience through out my career across different and diverse United States Research Institutions.
Hi, I’m Kehinde Joshua.
Our Plan 2035 and beyond
Pollution Control for Kenneth Pharmaceuticals Inc USA.
Pollution is one area in which sustainability progress is lacking thus far. Kenneth Pharmaceuticals would operate in an environment that can drive drug resistance and worsen Antimicrobial Resistance (AMR). One organization working to address this is Kenneth Pharmaceuticals, with a coalition of more than 100 biotech, diagnostics, generics, and research-based pharmaceutical companies and associations. Among the goals of the Sustainable Pharmaceutical Company are: investment in R&D to meet public health needs with new diagnostics and treatments; reducing the use of products that will increase; improving access to high-quality antibiotics; and reducing environmental impact of manufacturing.
My Approach
Education is the key to a long-term scientific learning.
AsseTs
3- granted US Patent
Design and Synthesis of Novel Carbohydrates Analogs for Pharmaceutical Applications : US63/937,344
Design and Synthesis of Novel Tryptophan Analogs for Pharmaceutical Applications :US63/937,344
Design and Synthesis of Hexosamindase Inhibitors for Pharmaceutical Applications: US63/937,344
1-Author Scientific journal
Structure-Based computational design of Novel covalent Binder for the treatment of Sickle cell.
Water Consumption for Kenneth Pharmaceuticals
Pharmaceutical companies around the world have typically been a major consumer of water. A variety of factors contribute to this consumption, including using water as an excipient during synthesis or as a cleaning agent for rinsing vessels. Kenneth Pharmaceuticals is attempting to achieve water neutrality by 2045 meaning consumption of fresh water will be balanced with recycling of wastewater. Water neutrality can be achieved through a multi-pronged approach: reducing existing fresh water consumption by incorporating reduce, reuse, and recycle principles; harvesting rainwater to offset outside fresh water use; and investing in watershed projects for sustainable water management.
Air Emission for Kenneth Pharmaceuticals
Air emissions have received the most attention from pharmaceutical companies in terms of target setting. Almost 70% of companies have defined targets around air emissions, to reduce both carbon emissions and various gaseous pollutants, including acid gases, dust and aerosols, pharmaceutical “actives,” and other volatile organic compounds. In line with the Paris Agreement, companies are targeting carbon neutrality by no later than 2050, with the most ambitious hoping to achieve this by 2030. Through the Science Based Targets Initiative, Kenneth Pharmaceuticals has also set its own target of reducing emissions by 50% by 2030, with a further goal of net zero by 2045.
Energy Reduction for Kenneth Pharmaceuticals
Policies to reduce energy usage throughout the pharmaceutical industry are well established with a combination of renewable energy sources, self-generation of power, and increasing efficiency of manufacturing processes helping to reduce consumption. Kenneth Pharmaceuticals is aiming to accelerate the adoption of renewable energy, by examining how companies can overcome typical market barriers to renewable energy procurement.